RFK Jr. wants Americans to use peptides that were banned over safety risks
The FDA may allow compounding pharmacies to make 14 restricted peptides, reversing a 2023 safety decision.
Presidential candidate and anti-vaccine activist Robert F. Kennedy Jr. is campaigning to end what he calls the FDA's "war on peptides," pushing the agency to lift restrictions on over a dozen injectable treatments. These peptides, including popular compounds like BPC-157, CJC-1295, and Ipamorelin, were banned in 2023 after the FDA reclassified them as posing "significant safety risks" due to a complete lack of randomized controlled trial data proving efficacy or safety. Kennedy, a self-proclaimed "big fan" who used them for injuries, discussed his plan on Joe Rogan's podcast, arguing for increased access despite the regulatory action taken against unproven claims from wellness influencers and biohackers.
The FDA is now reportedly moving to allow compounding pharmacies to produce 14 of these currently restricted peptides, a policy shift that has raised alarms within the agency and among medical experts. Top FDA leaders reportedly have "reservations" that the decision appears politically motivated rather than evidence-based. Experts like Eric Topol of Scripps Research warn the data is "woefully minuscule" and that these peptides represent a serious liability, with potential dangers including spurring cancer growth, causing hormonal imbalances, and risks from impurities in gray-market products. The move follows incidents like two women becoming critically ill after peptide injections at a Las Vegas anti-aging conference, highlighting the tangible safety concerns Kennedy's policy would embrace.
- RFK Jr. is pushing the FDA to reverse its 2023 ban on over a dozen peptide treatments classified as posing "significant safety risks."
- The FDA is reportedly preparing to allow compounding pharmacies to make 14 restricted peptides, including BPC-157 and CJC-1295, despite internal reservations.
- Medical experts warn of cancer risks and hormonal imbalances, citing a complete lack of randomized trial data and past incidents of critical illness from injections.
Why It Matters
This politicizes drug safety regulation, potentially exposing the public to unproven, risky treatments based on influencer trends rather than science.